Zevra Therapeutics (ZVRA) shares rallied 21.9% in the last trading session to close at $5.48. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 3.2% loss over the past four weeks. The stock rallied after the FDA indicated that it would convene a meeting with the recently formed Genetic Metabolic Diseases Advisory Committee to review the company’s new drug application (NDA) for pipeline candidate arimoclomol. Th ...